352 related articles for article (PubMed ID: 28114256)
1. Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.
Christiansen SA; Khan S; Gibney GT
Cancer J; 2017; 23(1):59-62. PubMed ID: 28114256
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
3. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice.
Silva IP; Long GV
Curr Opin Oncol; 2017 Nov; 29(6):484-492. PubMed ID: 28914644
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the immune system for the treatment of melanoma: current status and future prospects.
Guennoun A; Sidahmed H; Maccalli C; Seliger B; Marincola FM; Bedognetti D
Expert Rev Clin Immunol; 2016 Aug; 12(8):879-93. PubMed ID: 27070898
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for melanoma.
Cuevas LM; Daud AI
Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
[TBL] [Abstract][Full Text] [Related]
7. Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response.
Gingrich AA; Kirane AR
Surg Oncol Clin N Am; 2020 Jul; 29(3):467-483. PubMed ID: 32482321
[TBL] [Abstract][Full Text] [Related]
8. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
Hermel DJ; Ott PA
Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetic and immunotherapeutic targets in metastatic melanoma.
Melis C; Rogiers A; Bechter O; van den Oord JJ
Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489
[TBL] [Abstract][Full Text] [Related]
11. Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era.
Izar B; Regan MM; McDermott DF
Cancer J; 2017; 23(1):63-67. PubMed ID: 28114257
[TBL] [Abstract][Full Text] [Related]
12. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].
Okuyama R
Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
Johnson DB; Sosman JA
JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
[TBL] [Abstract][Full Text] [Related]
15. The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.
Naderi-Azad S; Sullivan R
Expert Rev Anticancer Ther; 2020 Feb; 20(2):131-136. PubMed ID: 32003263
[No Abstract] [Full Text] [Related]
16. Sequencing of New and Old Therapies for Metastatic Melanoma.
Ratterman M; Hallmeyer S; Richards J
Curr Treat Options Oncol; 2016 Oct; 17(10):52. PubMed ID: 27515170
[TBL] [Abstract][Full Text] [Related]
17. Novel Targets for the Treatment of Melanoma.
Ambrosi L; Khan S; Carvajal RD; Yang J
Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
[TBL] [Abstract][Full Text] [Related]
18. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
19. The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.
Margolin K
Curr Treat Options Oncol; 2016 Sep; 17(9):48. PubMed ID: 27461037
[TBL] [Abstract][Full Text] [Related]
20. Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.
Mandalà M; Tondini C; Merelli B; Massi D
Am J Clin Dermatol; 2017 Oct; 18(5):597-611. PubMed ID: 28432648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
